CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

GSK, Moderna settle patent dispute over Moderna COVID, RSV shots

By Reuters News

By Blake Brittain

Nov 6 (Reuters) - British drugmaker GSK GSK.L has settled lawsuits that accused Moderna's MRNA.O COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.

  • Moderna said in a Friday press release that it settled GSK's patent litigation in the US and Europe on October 28 and that the companies "granted patent cross-licenses in the field of infectious disease and are not obligated to make payments of any kind in connection with such licenses."

  • A GSK spokesperson said the company was "pleased to have reached a resolution that provides clarity for both companies and enables continued focus on advancing innovation for patients."

  • The companies asked a Delaware federal court on Friday to dismiss GSK's US infringement claims with prejudice, which means they cannot be refiled

  • GSK sued Moderna in 2024 over lipid nanoparticle technology used in the vaccines to transport fragile messenger RNA (mRNA) into the human body

  • GSK separately filed a similar lawsuit against Pfizer and BioNTech over their COVID-19 vaccine earlier that year, which is still ongoing

  • The lawsuits are part of a web of US court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against Pfizer in 2022

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.